TABLE 2.
Descriptive analysis of hepatitis B antiviral treatment nucleoside analogs medications in the “4 + 7”pilot cities.
| Categories | DDDs (million) | Expenditures (million CNY) | DDDc (CNY) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar.-Dec. 2018 | Mar.-Dec. 2019 | Growth rate (%) | Mar.-Dec. 2018 | Mar.-Dec. 2019 | Growth rate (%) | Mar.-Dec. 2018 | Mar.-Dec. 2019 | Growth rate (%) | |
| Selected medications | 61.65 | 135.06 | 119.09 | 842.71 | 352.33 | −58.19 | 13.67 | 2.61 | −80.92 |
| Entecavir | 52.96 | 111.36 | 110.28 | 729.12 | 282.97 | −61.19 | 13.77 | 2.54 | −81.54 |
| Tenofovir Fumarate | 8.69 | 23.70 | 172.86 | 113.60 | 69.36 | −38.94 | 13.08 | 2.93 | −77.62 |
| Alternative medications | 13.14 | 9.17 | −30.22 | 142.33 | 91.43 | −35.76 | 10.83 | 9.97 | −7.93 |
| Lamivudine | 1.50 | 0.78 | −48.11 | 40.92 | 19.55 | −52.22 | 27.36 | 25.20 | −7.92 |
| Adefovir dipivoxil | 9.34 | 6.51 | −30.28 | 59.25 | 37.81 | −36.19 | 6.35 | 5.81 | −8.48 |
| Telbivudine | 2.31 | 1.89 | −18.45 | 42.16 | 34.07 | −19.19 | 18.24 | 18.07 | −0.91 |
| NAs | 74.79 | 144.23 | 92.85 | 985.04 | 443.76 | −54.95 | 13.17 | 3.08 | −76.64 |
DDDs: Defined Daily Doses; DDDc: Defined Daily Drug cost; CNY: chinese yuan; NAs: Nucleoside Analogs. The bold value meaning was classification of antiviral medications of hepatitis B virus in this study.